LUCENTIS was the first FDA-approved anti-VEGF* medicine for diabetic retinopathy (DR) with or without diabetic macular edema (DME)
Two studies showed significant regression, or improvement, of DR with LUCENTIS
Improvements of 2 or more steps were shown in 2 studies of a total of 473 people who had DR with DME after 2 years of treatment:
Improvements of 3 or more steps were shown in the same 2 studies of a total of 473 people who had DR with DME after 2 years of treatment:
In a third study, 189 affected eyes of people who had DR with and without DME were treated monthly with LUCENTIS for 3 months, followed by treatment as required for 2 years:
In 2 studies of a total of 507 people who had DR with DME after 2 years:
LUCENTIS can also help improve† vision in people who have DR with DME
In the same 2 studies, more people who received LUCENTIS monthly were able to read an additional 15 letters on an eye chart at 2 years:
†Improvement is defined as reading an additional 15 or more letters on an eye chart.
Patient support for people with DR
Or call 1-866-LUCENTIS (1-866-582-3684), Monday through Friday, 9 AM-8 PM ET.
See how LUCENTIS may help people who have DR with DME